Microscopic structure of the large intestinal mucosa in piglets during an antibiotic-associated diarrhea.
Antibiotic-associated diarrhea (AAD) is caused by the treatments of broad-spectrum antimicrobials that seriously affect the activity and composition of the large intestinal microflora. The pathogenic bacteria or low concentration of short-chain fatty acids (SCFAs) has been repeatedly discussed in relation to AAD. Recently, we reported the detection of a large amount of succinate and lactate in the diarrheal feces in AAD-induced piglets. In this study, we investigated histologically the large intestinal mucosa in AAD-induced piglets, in which succinate and lactate were accumulated. AAD was induced in the piglets by an oral dose of polymyxin B sulfate (PL) or by an intra-muscular injection of enrofloxacin (ERFX). When the piglets were defecating diarrheal feces with a high concentration of succinate and/or lactate, the large intestine was removed and separated into four segments (cecum, gyri centripetales, gyri centrifugales, and rectum). Healthy piglets were used as the control. In the AAD-induced piglets, the lamina propria was edematous in the gyri centripetales. Piglets treated with ERFX were also edematous in gyri centrifugales. These edematous lamina propria contained larger amounts of inflammatory cells than observed in control tissues. ERFX-treated piglets had a more shallow crypt than PL-treated and control piglets. The mucosal tissue of the large intestine was more seriously damaged in the ERFX- than in the PL-treated piglets, which might have been caused by the high succinate and low SCFAs concentration in the digesta.
Tsukahara
Takamitsu
T
Laboratory of Animal Science, Kyoto Prefectural University, Shimogamo, Kyoto, Japan.
Iwasaki
Yoshie
Y
Nakayama
Keizo
K
Ushida
Kazunari
K
D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D000890:Anti-Infective Agents / Q000009:adverse effects*; D003967:Diarrhea / Q000139:chemically induced* / Q000382:microbiology / Q000473:pathology / Q000662:veterinary*; D000077422:Enrofloxacin; D024841:Fluoroquinolones; D007420:Intestine, Large / Q000187:drug effects* / Q000382:microbiology / Q000473:pathology*; D008297:Male; D011112:Polymyxin B / Q000009:adverse effects*; D015363:Quinolones / Q000009:adverse effects*; D013552:Swine; D013553:Swine Diseases / Q000139:chemically induced* / Q000382:microbiology / Q000473:pathology*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D000077422:Enrofloxacin; D011112:Polymyxin B